Development and characterization of a novel in vivo model of carcinoid syndrome

Keyphrases

• In Vivo Model 100%
• Carcinoid Syndrome 100%
• Valvular Heart Disease 50%
• Diarrhea 33%
• Liver Metastasis 33%
• BON Cells 33%
• Mesenteric Fibrosis 33%
• Liver 16%
• Spleen 16%
• Tumor Metastasis 16%
• Clinical Syndromes 16%
• Novel Treatments 16%
• Octreotide 16%
• Serum Serotonin 16%
• Carcinoid 16%
• Systemic Circulation 16%
• Carcinoid Tumor 16%
• Bioactive 16%
• Histopathological Examination 16%
• Athymic nude Mice 16%
• 5-hydroxyindoleacetic Acid (5-HIAA) 16%
• Echocardiographic Evaluation 16%
• Long-acting Somatostatin Analogues 16%
• Bevacizumab 16%
• Vascular Endothelial Growth Factor Inhibitors 16%
• Liver Manifestations 16%
• Cardiac Valvular Disease 16%

Medicine and Dentistry

• Carcinoid Syndrome 100%
• Disease 60%
• Valvular Heart Disease 60%
• Diarrhea 40%
• Liver Metastasis 40%
• Fibrosis 40%
• Carcinoid 40%
• Sequela 20%
• Metastatic Carcinoma 20%
• Clinical Syndrome 20%
• Serotonin 20%
• Octreotide 20%
• Somatostatin Derivative 20%
• Carcinoid Cell Line 20%
• Systemic Circulation 20%
• 5 Hydroxyindoleacetic Acid 20%
• Bevacizumab 20%
• Vasculotropin Inhibitor 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Carcinoid Syndrome 100%
• Disease 60%
• Carcinoid 60%
• Valvular Heart Disease 60%
• Diarrhea 40%
• Liver Metastasis 40%
• Fibrosis 40%
• Syndrome 20%
• Metastasis 20%
• Serotonin 20%
• Nude Mouse 20%
• Octreotide 20%
• Somatostatin Derivative 20%
• Systemic Circulation 20%
• Vasculotropin Inhibitor 20%
• Bevacizumab 20%
• 5 Hydroxyindoleacetic Acid 20%